Claims for harm from Allergan implants in New Jersey

MDL 2921 — In re Allergan BIOCELL Textured Breast Implant Products Liability Litigation — is consolidated in the U.S. District Court for the District of New Jersey before the Honorable Brian R. Martinotti. New Jersey is both the MDL forum state and an active plaintiff state with its own cosmetic surgery market in northern New Jersey, the Jersey Shore, and the New York metropolitan area suburbs. New Jersey has a 2-year personal injury statute under N.J.S.A. 2A:14-2 with the discovery rule. Mediation sessions between Allergan/AbbVie and plaintiffs' leadership were ongoing through late 2025. A July 14, 2026 order (CMO 42) set a final pretrial conference on Oct. 6, 2026 for the first two bellwether cases, and AbbVie reported that in June 2026 it agreed to resolve substantially all U.S. BIA-ALCL lawsuits. New Jersey plastic surgeons placed significant BIOCELL products from 2005–2019 in northern New Jersey and the Shore area. New Jersey BIA-ALCL patients have the most direct access to MDL 2921 proceedings.